10,706
Total Claims
$4.4M
Drug Cost
1,094
Beneficiaries
$4,027
Cost/Patient
Peer Comparison vs. 6,382 Endocrinology providers
+2%
Cost per patient vs peers
$4,027 vs $3,933 avg
-22%
Brand preference vs peers
39.8% vs 51.2% avg
Brand vs Generic
60% generic
Brand: 4,107 claims · $4.1M
Generic: 6,210 claims · $214K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 311 | $557K |
| Semaglutide | 320 | $535K |
| Empagliflozin | 228 | $304K |
| Teriparatide | 42 | $245K |
| Dapagliflozin Propanediol | 164 | $179K |
| Tirzepatide | 93 | $178K |
| Insulin Aspart | 121 | $175K |
| Insulin Lispro | 112 | $132K |
| Abaloparatide | 31 | $117K |
| Insulin Lispro | 80 | $114K |
| Insulin Glargine,hum.Rec.Anlog | 119 | $102K |
| Insulin Degludec | 93 | $82K |
| Evolocumab | 82 | $82K |
| Insulin Lispro | 16 | $79K |
| Levothyroxine Sodium | 728 | $75K |
Prescribing Profile
Patient Profile
74
Avg Age
63%
Female
1.19
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About